Scott Gottlieb Net Worth – Scott Gottlieb is an American physician, medical policy expert, and public health advocate who served in the Food and Drug...
Scott Gottlieb
Biographical Data, Scott Gottlieb |
|
|---|---|
| Age | 50 Years Old |
| Height | 5.8ft |
| Weight | NA |
| Eye Colour | Black |
| Hair Colour | Black |
Facts About Scott Gottlieb
- Scott is an American physician and former commissioner of the Food and Drug Administration (FDA).
- While at the FDA, he was responsible for approving multiple new drugs, including some designed for weight loss.
- Scott also spoke out about the opioid crisis and the epidemic use of electronic cigarettes.
- Scott is a member of the board of directors of several companies, including Pfizer and Illumina.
- Scott is a frequent contributor to The Wall Street Journal and other publications.
Relevant People & Companies
Latest News About Scott Gottlieb
Scott Gottlieb is a physician and worked for the Food and Drug Administration from May 2017 to April 2019. Scott is also a partner at the venture capital firm...
Scott Gottlieb Networth
Dr. Scott Gottlieb, Director of Pfizer, Scott has a net worth of $5 million in 2023. He owns 4000 PFE shares worth $205,280 and 4804 CBMX shares valued at $30,025. He earns $231,621 as an Independent Director at Pfizer. He made six transactions at Pfizer in the past three years, with his largest purchase being 3000 units worth $104.16K in August 2019. His most recent transaction was a purchase of 1000 units worth $37,000 on January 31, 2020.
Scott Gottlieb Biography
Scott Gottlieb is a highly respected American physician and health policy expert who served as the 23rd Food and Drug Administration Commissioner from 2017 to 2019. He received his education from top-tier institutions, including Princeton University and Harvard Medical School. He has affiliations with prestigious organizations like the Council on Foreign Relations and the American Enterprise Institute. Before his role as Commissioner, Gottlieb held the unique position of Deputy Commissioner for Medical and Scientific Affairs at the FDA from 2010 to 2011. His impressive background makes him a true authority in his field.
